137 related articles for article (PubMed ID: 33764396)
1. TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis.
Cordel N; Derambure C; Coutant S; Mariette X; Jullien D; Debarbieux S; Chosidow O; Meyer A; Bessis D; Joly P; Mathian A; Levesque H; Sabourin JC; Tournier I; Boyer O;
Rheumatology (Oxford); 2021 Dec; 60(12):5863-5867. PubMed ID: 33764396
[TBL] [Abstract][Full Text] [Related]
2. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
Pinal-Fernandez I; Ferrer-Fabregas B; Trallero-Araguas E; Balada E; Martínez MA; Milisenda JC; Aparicio-Español G; Labrador-Horrillo M; Garcia-Patos V; Grau-Junyent JM; Selva-O'Callaghan A
Rheumatology (Oxford); 2018 Feb; 57(2):388-396. PubMed ID: 29149307
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
4. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
5. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
7. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies.
Ly NTM; Ma N; Ueda-Hayakawa I; Nguyen CTH; Anada R; Okamoto H; Fujimoto M
J Dermatol Sci; 2021 Dec; 104(3):177-184. PubMed ID: 34772582
[TBL] [Abstract][Full Text] [Related]
9. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
10. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
11. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
Cordel N; Dechelotte B; Jouen F; Lamb JA; Chinoy H; New P; Vencovsky J; Mann H; Galindo-Feria AS; Dani L; Selva-O'Callaghan A; Werth VP; Ravishankar A; Landon-Cardinal O; Tressières B; Boyer O
Rheumatology (Oxford); 2023 Apr; 62(4):1711-1715. PubMed ID: 36250907
[TBL] [Abstract][Full Text] [Related]
12. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
[TBL] [Abstract][Full Text] [Related]
13. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays.
Labrador-Horrillo M; Martínez MA; Selva-O'Callaghan A; Trallero-Araguás E; Balada E; Vilardell-Tarrés M; Juarez C
Ann Rheum Dis; 2012 Jun; 71(6):993-6. PubMed ID: 22294626
[TBL] [Abstract][Full Text] [Related]
14. Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis.
Megremis S; Walker TDJ; He X; O'Sullivan J; Ollier WER; Chinoy H; Pendleton N; Payton A; Hampson L; Hampson I; Lamb JA
Commun Biol; 2021 Mar; 4(1):419. PubMed ID: 33772100
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
16. Expression of the autoantigen TRIM33/TIF1γ in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress.
Scholtissek B; Ferring-Schmitt S; Maier J; Wenzel J
Clin Exp Dermatol; 2017 Aug; 42(6):659-662. PubMed ID: 28639716
[TBL] [Abstract][Full Text] [Related]
17. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
18. Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis.
Nakanishi Y; Yamaguchi K; Yoshida Y; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Miyamoto S; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
Intern Med; 2020 Oct; 59(20):2553-2558. PubMed ID: 32581161
[TBL] [Abstract][Full Text] [Related]
19. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
20. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
